

Cumulative Index 2003

Volume 30

March	ETHICS IN PERINATAL MEDICINE, pages 1–187
June	EVIDENCE-BASED MEDICINE, pages 189–438
September	MATERNAL-FETAL SURGERY, pages 439–649
December	PRETERM LABOR, pages 651–894

Note: Page numbers of article titles are in **boldface** type.

A

Abacavir, for HIV infection, in pregnancy, labor and delivery, 862

Abortion

- induced
 - fetal personhood and, 158
 - for anomalies, 113–114
 - availability of, 117
 - decision-making on, 113–114, 118–119
 - legality of, 71
 - methods for, 119
 - viability definition and, 119–121
- for genetic indications, 90–91
- for nonmedical reasons, FIGO ethical guidelines for, 57–59
- for sex selection, 89

selective. *See* Selective termination.

terminology recommendations for, 20

Academic performance, follow-up data in, 231–232

Acardiae twin, in twin reversed arterial perfusion sequence, 602–603

Access to care, in managed care, 172–173

AIDS. *See* Human immunodeficiency virus infection.

American College of Surgeons, guidelines of, for maternal-fetal surgery, 142

American Society for Reproductive Medicine Ethics Committee, on gender selection, 75–76

Aminophylline, for preterm labor, 821

Amniocentesis

- for anomaly detection
 - emotional support for, 115
 - failure to inform about, 114
- premature membrane rupture in, amniopatch technique for, 574–580
- serial, for twin–twin transfusion syndrome, 594–597

Amnionitis. *See* Chorioamnionitis.

Amniotic fluid

- abnormal volumes of. *See* Oligohydramnios; Polyhydramnios.
- amniopatch technique involving, for premature membrane rupture, 574–580, 586–587
- culture of, 683–684
- in gastroschisis, 559–564
 - exchange or infusion of, 561–564
 - inflammatory effects of, 559–561

Amoxicillin, for intrauterine infections, 688–689, 691

Ampicillin, for intrauterine infections, 687, 689

Ampravavir, for HIV infection, in pregnancy, labor and delivery, 863

Anastomoses, placental, in twin–twin transfusion syndrome, 592–593

Anencephaly, viability questions in, 119–121

Aneuploidy, nuchal translucency screening for, 95–102

- reliability of, 95–98
- respect for autonomy in, 100
- risks versus benefits of, 98–99

Anhydramnios
in fetal distal urinary obstruction, 507, 511-512, 515
in gastroschisis, 553

Anomalies, fetal. *See* Fetus, anomalies in.

Antenatal surgery. *See* Maternal-fetal surgery.

Antibiotics
for asymptomatic premature infants, treatment decisions in. *See* Treatment decisions.
for intrauterine infections, 687-691, 718-720
for preterm premature rupture of membranes, 828-829

Aortic stenosis, treatment of, 544-545

Apnea, neonatal, methylxanthines for, treatment decisions in. *See* Treatment decisions.

Arachidonic acid, in prostaglandin synthesis, in uterine activity, 807

Ascites, in distal urinary tract obstruction, 510

Assisted reproduction technologies
multifetal pregnancy in. *See* Multifetal pregnancy.
preterm birth risk with, 659

Atazanvir, for HIV infection, in pregnancy, labor and delivery, 863

Atosiban, for preterm labor, 822, 849

Atrial septum, intact, treatment of, 545-546

Autonomy
in decision-making about fetal anomalies, 118-119
in maternal-fetal surgery for spina bifida, 453-455
reproductive freedom component of, 114
respect for, in nuchal translucency screening, 100

B

Bacterial vaginosis, preterm birth in, 655-656, 686-687, 690-691

Balloon
for tracheal occlusion, in congenital diaphragmatic hernia, 469-473
for valvuloplasty. *See* Valvuloplasty, balloon.

Bayley Scales of Infant Development, follow-up data in, 228

Bedrest, for preterm labor, 813-814

Benchmarking techniques, 343-350
abuses of, 347
limitations of, 345
patient protection in, 348
to improve quality of practice, 348-349
uses of, 344-346

Beneficence
in fetal anomaly management, 122-123
in maternal-fetal surgery for spina bifida, 456-457
in nuchal translucency screening, 98-99

Bentham, Jeremy, ethics theory of, 6

Beta-adrenergic agonists, for preterm labor, 818-820

Beta-sympathomimetic agents, for preterm labor, 817-820

Betamethasone, antenatal, for fetal maturation, 829-833

Biopsy, kidney, in distal urinary tract obstruction, 513

Bipolar coagulation, of umbilical cord, in multifetal pregnancies, 611-616

Birthweight, in multifetal pregnancy, selective reduction effects on, 106-107

Bladder
embryology of, 508
obstruction of. *See* Urinary tract obstruction, distal.

Blastocyst, 29, 39

Blastomeres, 29

Bleeding, vaginal, preterm birth in, 657

Blood transfusions, refusal of, in pregnancy, 130-131, 135

Brain death, 36

Braxton Hicks contractions, 809-810

Breastfeeding, avoidance of, in HIV infection, 872

Bronchopulmonary sequestration
diagnosis of, 482-483
natural history of, 484
size of, 481
surgical treatment of, 486-487

C

Calcium, in uterine activity, 806-807

Calcium channel blockers, for preterm labor, 820-821, 849-850

Capitation, in managed care, 170

Carder, Angela, court-ordered cesarean section on, 129–134

Care, access to, in managed care, 172–173

Catheters

- for thoracoamniotic shunting, 485–486
- for vesicoamniotic shunting, 513–515

Cephalocentesis, in hydrocephalus, 533

Cerebral palsy, motor development in, 227–228

Cervicovaginal fibronectin. *See* Fibronectin, fetal.

Cervix

- incompetence of
 - preterm labor in, 808–809
 - ultrasound evaluation of, 749–752
- length of, preterm birth risk and, 654
- preparation of, for labor, 810
- ultrasound evaluation of, 735–755
 - in preterm birth prediction, 738–749
 - cervical incompetence in, 749–752
 - in asymptomatic women, 738–741, 744–747
 - in multifetal pregnancy, 746–747
 - in singleton pregnancy, 744–749
 - in symptomatic women, 742–743
- landmarks for, 736
- technique for, 736–738
- versus clinical examination, 736

Cesarean delivery

- for HIV infection, 865, 868
- for nonmedical reasons, FIGO ethical guidelines for, 53–54
- managed care impact on, 176–177
- refusal of
 - legal issues in, 129–133
 - survey on, 134–139

Chemical phenomenon, in gastroschisis, 553

Chiari malformation, with myelomeningocele, 523–526

Chorioamnionitis

- in maternal–fetal surgery, for lung lesions, 487
- neonatal outcomes in, 685
- preterm birth in, 655–656
 - asymptomatic, 681
 - chronicity of, 682–682
 - clinical features of, 680–681

corticosteroids for, 830

diagnosis of, 679

mechanisms of, 684

organisms causing, 683–684

origin of, 685

premature rupture of membranes in, 691

treatment of, 687–691

versus gestational age, 681–682

Chorionic villi sampling

- before multifetal pregnancy reduction, 632
- before selective reduction, 108–109
- premature membrane rupture in, amniopatch technique for, 574–580

Chromosomal abnormalities

- in discordant twins, 603
- in gastroschisis, 552
- in multifetal pregnancies, 605–606, 631–632
- in twin reversed arterial perfusion sequence, 602
- selective termination for. *See* Selective termination.

Chronic lung disease, prevention of, dexamethasone in, evidence-based decision-making in, 238–239

Clewell, William, maternal–fetal surgery research by, 442–445

Clindamycin, for intrauterine infections, 689

Cochrane neonatal systematic reviews, 285–304, 335–336, 391–393

- results of, 287–299
 - characteristics of included trials, 288–289
 - distribution across subject areas, 288
 - growth of output, 287–288
 - observations on review
 - methodologies, 299–300
 - reviewers' conclusions, 291, 299
 - size and precision of estimate of treatment effect, 290–291
 - size of reviews, 290
 - therapies with extensive versus limited testing, 291
 - survey methods in, 286–287

Cognitive development, follow-up data in, 228–230

Common sense, in ethics, 9

Communication, 17–25

- alternative word choices for, 23–24
- discriminatory, 18–19
- impact on memory, 17–18

importance of, 17-18
medical language for, 19
obstetric language for, 20
of fetal anomaly test results, 115-117
prenatal diagnosis language for, 20-24
sexist, 18-19

Confidentiality, of genetic data, 87-88

Congenital anomalies. *See* Fetus, anomalies in.

Congenital cystic adenomatoid malformation, of lung, 481-492
animal studies of, 484-485
clinical features of, 481
diagnosis of, 482-483
natural history of, 484
pathology of, 482
size of, 482
surgical treatment of, 485-488
types of, 482

Congenital diaphragmatic hernia, 465-479
animal studies of, 467
delivery with, 473-474
incidence of, 465
mortality in, 465, 467, 475
natural history of, 466-467
prognosis for, 466-467
treatment of
 postnatal, 474-475
 prenatal, 467-473
 ultrasonography in, 466-467

Congenital heart disease, 541-550
diagnosis of, 542-543
etiology of, 543
in gastroschisis, 554-555
treatment of
 anesthesia in, 547
 aortic stenosis, 544-545
 intact atrial septum, 545-546
 mitral stenosis, 545
 rationale for, 543-544
 right-sided defects, 546
 techniques for, 547-548

Consequentialism, 6

Constrictive phenomenon, in gastroschisis, 552-553

Contractions, uterine. *See* Uterus, contractions of; Home uterine activity monitoring.

Corpus luteum, ultrasonography of, 39

Corticosteroids, antenatal, for fetal maturation, 827-842
 American College of Obstetricians and Gynecologists opinion on, 837
 drug selection for, 830-833
 effects of, 827-828
 evidence-based decision-making in, 409-412

in preterm premature rupture of membranes, 828-830
National Institutes of Health
 recommendations on, 836-837
single versus multiple courses of, 833-835

Council of Europe, ethics code of, 51

Counseling
 on fetal anomalies
 postviability, 122-124
 previability, 118-119
 on selective termination, in multifetal pregnancies, 604-606

Cryoprecipitate, in amniopatch, for premature membrane rupture, 574-580, 586-587

Culture, of amniotic fluid, 683-684

Cystic adenomatoid malformation volume ratio, 484

Cystoscopy, for distal urinary tract obstruction, 515-516

Cytogenetic analysis, in multifetal pregnancies, 605

Cytokines
 in chorioamnionitis, 679, 684
 in gastroschisis, 557-558
 in preterm birth, 655-657

Cytomegalovirus infections, preterm birth in, 694

D

daVinci system, for maternal-fetal surgery, 528

De Lia, Julian, maternal-fetal surgery research by, 445-446

Death
 fetal, in maternal infections, 692-694
 maternal, pregnancy management guidelines for, 53

Decision-making
 evidence-based. *See* Evidence-based decision-making.
 in genetic counseling, 84-86
 in preimplantation diagnosis, of Down syndrome, 74-75
 on abortion
 for anomalies, 113-114, 118-119, 122-124
 for trisomy 13, 121-122
 for trisomy 18, 121-122

Declaration of Helsinki, 60-63

Delavirdine, for HIV infection, in pregnancy, labor and delivery, 862

Delivery, managed care impact on, 175-177

Denver shunt, in hydrocephalus, 534-535

Deontology, 6

Department of Health and Human Services, maternal-fetal surgery research guidelines of, 146-152

Dexamethasone

- antenatal, for fetal maturation, 829-833
- to prevent chronic lung disease, evidence-based decision-making in, 238-239

Diagnostic tests, 189-204

- benefit of, to patient, 201-202
- posttest probability of disease and, 201
- pretest probability of disease and, 201
- reproducibility of, 201
- research literature on, 197-202
 - case scenario in, 197, 202
 - search of, for best available study, 197-198
 - study appropriateness in, 199-200
 - study validity in, 198-199
 - screening, 196-197
 - sensitivity, specificity, and likelihood ratio in, 190-191, 200

Diaphragmatic hernia. *See* Congenital diaphragmatic hernia.

Diazoxide, for preterm labor, 822

Didanosine, for HIV infection, in pregnancy, labor and delivery, 859-860, 862

Diltiazem, for preterm labor, 849-850

Disability

- prevention of, with preimplantation genetic diagnosis, controversy over, 72-75
- threat of, maternal-fetal surgery for spina bifida and, 459-460

Doppler studies, in congenital heart disease, 542-543, 545

Down syndrome

- nuchal translucency screening for, 95-102
 - reliability of, 95-98
 - respect for autonomy in, 100
 - risks versus benefits of, 98-99
- preimplantation diagnosis of, decision-making in, 74-75
- prenatal detection of, failure to inform about, 114

Drainage

- in thoracoamniotic shunting, 485-486
- in vesicoamniotic shunting, 513-515
- of sacrococcygeal teratoma, 497-498, 501

Dystocia, with large sacrococcygeal teratoma, 494

E

Economic issues

- in managed care, 169-171
- in multifetal pregnancies, 624-625
- in preterm birth, 666, 757-758
 - home uterine activity monitoring
 - impact on, 783-784, 787

Education, in ethics, 1-15

- core generic course in, 11-13
- for perinatal medicine, 13
- impact of, 13-14
- introduction to, 10-11
- phases of, 10-13
- principles of
 - definitions of, 1-2
 - medical ethics versus general ethics, 2-3
 - moral certainty, 6-8
 - reasoning, 3-5
 - trust, 8-9
- process of, 9-10
- purpose of, 9-10
- theories for, 6-8

Efavirenz, for HIV infection, in pregnancy, labor and delivery, 863

Electrical properties, of myometrium, 667-669

Electromyography, uterine, 670-674

Embolization, of umbilical vessels, in selective termination, in multifetal pregnancies, 606-608

Embryo(s)

- as beginning of human life, 32-33
- definition of, 36
- extracorporeal, moral status of, 70-71
- research on, ethical issues in, 36-37
- transfer techniques for, preterm birth risk in, 659
- ultrasonography of, 40-42

Embryo-chorionic circulation, ultrasonography of, 40

Embryogenesis, 29-30

Emotional development, follow-up data in, 230

Emotional support, for fetal anomaly detection and management, 115

Emtricitabine, for HIV infection, in pregnancy, labor and delivery, 862

Endometrium, microorganism colonization of, preterm birth in, 656

Endoscopy, for premature ruptured membrane assessment, 580-584

Enfuvirtide, for HIV infection, in pregnancy, labor and delivery, 863

Enzyme-linked immunosorbent assay for fetal fibronectin, 704 for salivary estriol, 721

Equipoise criterion, in maternal-fetal surgery for myelomeningocele, 162-163

Erythromycin, for intrauterine infections, 687-691

Estriol, salivary, as preterm birth predictor, 720-727
background of, 720-723
confounding factors in, 721-723
in asymptomatic women, 723-724
in multifetal pregnancy, 726
in symptomatic women, 724-726
intervention studies of, 726-727

Ethanol, for preterm labor, 815-816

Ethics
codes of, 45-65
Council of Europe, 51
FIGO (International Federation of Gynecology and Obstetrics) Committee, for Study of Ethical Aspects of Human Reproduction, 51-58
for cesarean delivery for nonmedical reasons, 53-54
for induced abortion for nonmedical reasons, 57-59
for management of newborns at threshold of viability, 54-56
for management of severely malformed newborns, 56-57
for pregnancy management in sudden maternal death, 53
for prenatal diagnosis, 52-53
for research on human subjects, 59-63
from hospital ethics committees, 46-48
from international ethics committees, 49-58
from national ethics committees, 48-49
new technology impact on, 45-46
patient-physician relationship and, 46

United Nations Educational, Scientific, and Cultural Organization, 50

World Health Organization, 50-51
communication and, 17-25
definition of, 45
education in, 1-15
evidence-based. *See*
Evidence-based ethics
of beginning of human life, 27-44
of fetal anomaly screening, 113-126
of genetic counseling, 81-93
of managed care, 167-180
of maternal-fetal surgery
for congenital heart defects, 543
for multifetal pregnancy reduction, 623-624
for myelomeningocele, 155-165
for spina bifida, 449-464
autonomy in, 453-455
beneficence in, 456-457
clinical emphasis in, 451
controversy over, 449-450
elective interventions in, 458-459
moral ideas on, 451-453, 457-458
potential abuse of, 461-462
predisposition to treatment in, 460-461
religious context of, 452-453
risk considerations in, 457-458
threat of disability in, 459-460
uncertainty in, 455-456
vulnerability in, 454-455
in research programs, 141-153
of nuchal translucency screening, 95-102
of preimplantation diagnosis. *See*
Preimplantation genetic diagnosis
of refusal of treatment, 127-140
of selective reduction, 103-111

Ethnic factors, in preterm birth, 651, 656-657

Eugenics, 86-87

Evidence-based decision-making. *See also*
Therapeutic evidence;
Treatment decisions
follow-up data in, 217-250
choice of outcomes to study, 218-224
examples of, 238-240
group difference in, 233, 237-238
health-related quality of life, 224
neonatal outcome as predictor of, 225
neurodevelopment after age 2, 229-232

academic performance, 231–232
cognitive development, 229–230
motor development, 229
social and emotional development, 230
neurodevelopment at 1 to 2 years of age, 226–228
cognitive development, 228
hearing assessment, 226–227
motor development, 227–228
vision assessment, 227
no group difference in, 232–233
in neonatal intensive care unit. *See*
 Neonatal intensive care unit,
promoting uptake and use of, 389–402,
 403–417
 analysis of uptake process, 404–405
 clinician awareness of proven therapies, 391–393, 405–406
 clinician belief in evidence, 406
 clinician commitment to change, 407
 definition of effectiveness, 389–391
 dissemination of new information, 393–397
 clinician factors in, 396–397
 comparison of methods for, 394–396
 evaluation of new therapies, 390–391
 evidence to support particular strategy, 405
 examples of, 409–415
 antenatal steroids for fetal maturation, 409–412
 National Partnership to Help Pregnant Smokers Quit, 412–414
 smoking cessation in routine care, 414–415
 implementation, monitoring, and maintenance of change, 408
 inappropriate underuse of proven therapies, 397–399
 peer endorsement of evidence, 406–407
 perception of gap between practice and evidence, 407
 support for change by practice setting, 407–408
 synergistic effects of interventions, 408–409
teaching of, 419–433
 apply information to problem and evaluate outcome, 429–430
 critically appraise evidence, 428–429
 curriculum evaluation in, 430–431
 obtain information with maximum efficiency, 426–428
 recognize need for information and put in form of answerable question, 425–426
 strategies for, 421–423
 to faculty, 425
 to medical students, 423–424
 to residents and fellows, 424–425

Evidence-based ethics, for extremely premature infants, 363–387
 based on credible evidence, 366
 boundaries for care categories in, 379–381
 chance of survival and, 366
 cost-effectiveness in, 373–375
 definition of, 364
 effects on families in, 377–378, 382
 futility of care, 364–366
 need for improved studies of, 381
 outcome measurements in, 368–369
 patient factors in, 369–373
 preventing quandaries in, 382–383
 roles of parents and physicians in, 378–379
 treatment withdrawal in, 377
 types of therapeutic studies in, 367
 use of resources and distress to infants versus benefits, 375–376

Ex utero intrapartum treatment (EXIT), in congenital diaphragmatic hernia, 473–474

Experimental therapy, in managed care, 173

Extracorporeal membrane oxygenation, for congenital diaphragmatic hernia, 474–475

F

Fee for service, negotiated, in managed care, 170–171

Feminist ethics, 7

Ferritin, in gastroschisis, 558

Fertilization
 in vitro, multifetal pregnancy in, selective reduction in, 103–111
 life beginning at
 arguments against, 32–33
 arguments for, 31–32

Fetoscope
 iatrogenic membrane rupture from, amniopatch technique for, 574–580
 invention of, 440–441

Fetus

anomalies in, 113-126
communication about.
See Communication.
lethal, hospice care in, 123-124
management of
aggressive, 117, 122-124
balancing approach to,
117, 123
nonaggressive, 117, 122-124
options for, 117
postviability counseling and
decision-making on,
122-124
preimplantation detection of.
See Preimplantation
genetic diagnosis.
previability counseling and
decision-making on, 118-119
screening and detection of
emotional support in, 115
ethical basis of, 113-114
giving bad news after,
115-117
selective reduction for, 108-109
viability definition and, 119-122
fibronectin related to. *See*
Fibronectin, fetal.
genetic counseling related to. *See* Genetic
counseling.
maturation of, antenatal steroid therapy
in. See Corticosteroids, antenatal,
for fetal maturation.
personhood of, 31, 156-160, 449-452
research on, ethics guidelines for, 62-63
surgery on. *See* Maternal-fetal surgery.
ultrasonography of, 3D and 4D, 41-42
viability of. *See* Viability, of fetus
or newborn.

Fibrin formation, in amniopatch technique, 578

Fib, in glue, for premature rupture of
membranes, 585-586

Fibronectin, fetal
as preterm birth predictor, 702-720
assays for, 704-705
confounding factors in, 705
historical background of, 702-705
in asymptomatic women, 706-709
in multifetal gestations, 714-717
in symptomatic women, 710-714
intervention studies of, 717-720
in normal pregnancies, 702-704

FIGO (International Federation of Gynecology
and Obstetrics) Committee, for Study of
Ethical Aspects of Human Reproduction,
51-58

Financial considerations, in genetic
counseling, 92

Fluid therapy, for preterm labor, 814

Formulary, limited, in managed care, 173

G

Gamete intra-fallopian transfer, preterm birth
risk in, 659

Gastroesophageal reflux, treatment decisions
in. *See* Treatment decisions.

Gastroschisis, 551-572
amnioexchange and amnioinfusion
procedures for, 561-564
amniotic fluid impact on, 559-562
animal models of, 557-559
consequences of, 552-553
delivery in, 554
diagnosis of, 553
etiology of, 552
genetic factors in, 552
historical review of, 551
incidence of, 551
inflammation in, 557-559, 562-564
monitoring of, 553-554
outcome of, 555
postnatal care in, 554-555
prognosis for, 555-557
surgical treatment of, 554-555

Gender

medical language insensitive to, 19
prebirth selection for, 75-77, 89
sexist language and, 18-19

Gene therapy, preimplantation genetic
diagnosis and, 92

Genetic counseling, 81-93
counselor responsibilities in, 84-86
decision rights in, 84-86
directive, 82
discrimination resulting from, 88-89
history of, 81-82
illness versus health considerations in,
89-90
means of, 82-84
nondirective, 82, 84-86
on financial costs, 92
on monogenic diseases, 86-87
on pregnancy termination, 90-91
on preimplantation diagnosis, 92
on presymptomatic diagnostics,
confidentiality of data and, 87-88
on sex selection and determination, 89
religious considerations in, 91-92
stigmatization resulting from, 88-89

Gestational age

at delivery, tocolysis effects on, 852
versus intrauterine infections, 681-682

H

Harrison, Michael, maternal–fetal surgery research by, 441–442

Health, versus illness, genetic counseling and, 89–90

Health maintenance organizations. *See* Managed care.

Hearing assessment, follow-up data in, 226–227

Heart disease, congenital. *See* Congenital heart disease.

Hernia, diaphragmatic. *See* Congenital diaphragmatic hernia.

Highly active antiretroviral therapy, for HIV infection, in pregnancy, labor and delivery, 861

HIV infection. *See* Human immunodeficiency virus infection.

Home uterine activity monitoring, 757–804
after tocolysis, 787–791
clinical trials overview of, 759
comprehensive system versus self-palpation, 767–768
controversy over, 759–760
devices for, 765–766
during maintenance tocolytic therapy, 793–797
economic impact of, 783–784, 787
false versus true, 766
frequency of, 764–765
in multifetal pregnancy, 765, 781–782
in secondary prevention clinical trials, 768–787
in socioeconomically disadvantaged group, 783–784
in tertiary prevention clinical trials, 787–791
indications for, 757–759
miscellaneous studies on, 791–792
preterm contractions, 764–765
preterm labor symptoms and, 766–767
protocol for, 761–764
recording strips produced in, 761–762

Hospice care, in lethal fetal anomalies, 123–124

Hospital ethics committees, 46–48

Human Genome Project, genetic counseling and, 86–87

Human immunodeficiency virus infection, preterm labor in, 857–876
antenatal care in, 871
clinical situations in, 869–870
delivery mode in, 865

follow-up care in, 871
general laboratory testing in, 859–860
HIV testing in, 858–859
neonatal care in, 871–872
obstetric procedures in, 868–869
postpartum care in, 871
viral transmission prevention in, 860–868

Hydrocephalus, 443–445, 531–539
anomalies associated with, 531–533
classification of, 531–532
diagnosis of, 532–533
etiology of, 531–532
morbidity and mortality in, 532, 534–535
myelomeningocele with, 523, 525–526
prevalence of, 531
treatment of, 533–538

Hydronephrosis, in distal urinary tract obstruction, 510

Hydrops
in lung lesions, 481–486
in sacrococcygeal teratoma, 495–503

Hydroureters, in distal urinary tract obstruction, 510

17- α -Hydroxyprogesterone, for preterm labor, 822

Hyperglycemia, from ritodrine, 819–820

Hypnotics, for preterm labor, 821–822

Hypoplastic left heart syndrome
in aortic stenosis, 544–545
in intact atrial septum, 545–546
in mitral stenosis, 545

Hypoplastic right heart syndrome, 543, 546

Hypotension, in premature infants, inotropes for, treatment decisions in. *See* Treatment decisions.

I

Illness, versus health, genetic counseling and, 89–90

Implantation, as beginning of human life, 33

In vitro fertilization
multifetal pregnancy in, selective reduction in, 103–111
preterm birth risk in, 659

Incompetence, cervical, ultrasound evaluation of, 749–752

Indinavir, for HIV infection, in pregnancy, labor and delivery, 863

Indomethacin

for preterm labor, 816-817, 847, 849
prophylactic, in low birth weight infants,
evidence-based decision-making in,
239-240

Infections

neonatal effects of, 687
preterm birth in, 655-656,
677-700, 809
ascent of, 686
asymptomatic, 681
bacterial vaginosis, 686-687
chronicity of, 682-683
diagnosis of, 679-680
fetal death in, 694
fetal fibronectin in, 704, 717-720
historical review of, 677-679
markers of, 680
mechanisms of, 684
organisms causing, 683-684
origin of, 685
premature rupture of membranes
in, 691
sexually transmitted, 691, 693-694
treatment of, 687-691
types of, 680-681
versus gestational age, 681-682
viral, 694

Infertility, treatments for

multifetal pregnancy in, 103-105
religious teachings on, 34

**Inflammation, in gastroschisis, 557-559,
562-564****Informed choice, in maternal-fetal surgery for
spina bifida, 460-461****Informed consent**

for nuchal translucency screening, 100
for preimplantation genetic diagnosis, 69

**Inotropes, for hypotension, in premature
infants, treatment decisions in. *See
Treatment decisions.*****Intensive care unit, neonatal. *See under
Neonatal intensive care unit.*****Interleukin(s), in gastroschisis, 557-558,
562-563****International ethics committees**

codes of, 49-58
Council of Europe, 51
United Nations Educational, Scientific,
and Cultural Organization, 50
World Health Organization, 50-51

**International Federation of Gynecology and
Obstetrics (FIGO) Committee, for Study
of Ethical Aspects of Human
Reproduction, 51-58****International Fetal Medicine and Surgery
Society, 444****International Fetoscopy Group, 440-441****Intestine**

exteriorization of, in gastroschisis, 552
pathology of, in gastroschisis, 553-554

Intrauterine growth retardation

after multifetal pregnancy reduction, 631
in gastroschisis, 554, 563

**Intrauterine pressure catheters, for preterm
labor detection, 667****Isoxuprine, for preterm labor, 818****J****Justice principle, preimplantation genetic
diagnosis and, 69****K****Kant, Immanuel, ethics theory of, 6****Karyotyping, for genetic diagnosis in selective
reduction, 108-109****Keratinocyte growth factor, in congenital cystic
adenomatoid malformation, 482****Kidney**

biopsy of, in distal urinary tract
obstruction, 513
damage of, in urethral obstruction,
507-510

L**Labor and delivery. *See also Cesarean delivery.***

diagnosis of
clinical, 666-667
electromyography in, 670-674

in congenital diaphragmatic hernia,
473-474

in gastroschisis, 555
in HIV infection, 865, 868

in hydrocephalus, 533-534
in large sacrococcygeal teratoma, 494

premature. *See Premature labor
and delivery.*

preparatory stage of, 669-670

**Lamivudine, for HIV infection, in pregnancy,
labor and delivery, 862, 864****Language. *See Communication.*****Laser therapy**

for premature rupture of membranes,
584-586

for sacrococcygeal teratoma, 500–501
for selective termination, in multifetal pregnancies, 607, 610
for twin–twin transfusion syndrome, 595–597

Leg function, after myelomeningocele repair, 526

Legal issues
in managed care, 174–175
in refusal of treatment, 128–134
in viability definition, 119–122

Length of stay, for delivery, in managed care, 175–176

Leukocytes, in chorioamnionitis, 679

Life, 27–44
beginning of
at fertilization
 arguments against, 32–33
 arguments for, 31–32
 biologic view of, 28–29
 controversies on, 35–36
 embryo research and, 36–37
 embryogenesis and, 29–30
 religious teachings on, 33–35
 visualization of, 37–42
definition of, 27
ending of, controversies on, 35–36
personality and, 30–31

Life support, withholding or withdrawal of
for newborns at threshold of viability, 54–55
ethics of, 54–55
for severely malformed newborns, ethics of, 56–57

Lifestyle risks, for preterm birth, 659–660

Litigation, managed care and, 174–175

Liver, position of, in congenital diaphragmatic hernia, 466–467, 474

Lopinavir, for HIV infection, in pregnancy, labor and delivery, 863

Low birth weight infants
low bilirubin levels in, phototherapy for, treatment decisions in. *See* Treatment decisions.
prophylactic indomethacin in, evidence-based decision-making in, 239–240

Lung
 agenesis of, 483
 bronchopulmonary sequestration in, 481–484, 486–487
 congenital cystic adenomatoid malformation of, 481–492
hypoplasia of
 in congenital diaphragmatic hernia, 465–475
 in oligohydramnios, 507
maturation of, corticosteroids for. *See* Corticosteroids, antenatal, for fetal maturation.

Lung-to-head-ratio, in congenital diaphragmatic hernia, 466–467

Lysosomes, in uterine activity, 807

M

Magnesium preparations, for preterm labor, 814–815, 848

Magnetic resonance imaging, in hydrocephalus, 533

Magnetic resonance spectroscopy, in urine analysis, in distal urinary tract obstruction, 513

Managed care, 167–180
ethical issues in
 access to care, 172–173
 cesarean section, 176–177
 costs, 169–170
 experimental therapy, 173
 length of stay, 175–176
 level III neonatal care, 178
 limited formulary, 173
 litigation, 174–175
 patient education, 172
 patient-physician relationship, 168–169
 payment methodologies, 170–171
 physician selection, 171
 pre-certification, 172–173
 preventive services, 172
 quality management, 171–172
 range of benefits, 172
 referral to maternal fetal medicine specialists, 178–179
 role of, 173–174
 standards of practice, 171
 ultrasound use, 177–178
 history of, 167–168

Marketing, of preimplantation genetic diagnosis, 68–69

Maternal–fetal medicine specialists, referral to, in managed care, 178–179

Maternal–fetal surgery
 coercion in, 157
 ethics of
 in congenital heart disease, 543
 in multifetal pregnancy reduction, 623–624

in spina bifida, 449–464, 543, 623–624
for anomalies, counseling on, 118–119, 122–124
for complicated multifetal pregnancy management, 601–621
for congenital heart disease, 541–550
for diaphragmatic hernia, 465–479
for distal urinary obstruction, 507–519
for gastroschisis, 551–572
for hydrocephalus, 443–445, 531–539
for lung lesions, 481–492
for multifetal pregnancy reduction, 623–641
for myelomeningocele, 155–165, 521–530, 533
equipoise criterion in, 162–163
outcome of, 160–161
patient definition in, 156–160
research on, 160–163
risks of, 161–162
for premature ruptured membrane repair, 573–589
for sacrococcygeal teratoma, 493–506
for selective termination. *See* Selective termination.
for twin–twin transfusion syndrome. *See* Twin–twin transfusion syndrome.
history of, 439–447
research on, 141–153
current status of, 141–144
ethical concerns in, 145–146
federal rules on, 146–152
technical details of, 144–145
risks of, 144–145

Maternal mirror syndrome
fetal lung lesions and, 487–488
sacrococcygeal teratoma and, 496–497

Matrix metalloproteinases, in chorioamnionitis, 679, 684

Mechanical ventilation, for congenital diaphragmatic hernia, 474–475

Membrane rupture
iatrogenic, between twins, for twin–twin transfusion syndrome, 596
premature. *See* Premature ruptured membranes.

Mesenteric vascularization, in gastroschisis, 554

Methylxanthines, for neonatal apnea, treatment decisions in. *See* Treatment decisions.

Metronidazole, for intrauterine infections, 688–690, 718

Mezlocillin, for intrauterine infections, 687

32-Microglobulin measurement, in distal urinary tract obstruction, 512

Mill, John Stuart, ethics theory of, 6

Mirror syndrome
fetal lung lesions and, 487–488
sacrococcygeal teratoma and, 496–497

Mitral stenosis, treatment of, 545

Monitoring, of uterine contractions, at home. *See* Home uterine activity monitoring.

Monopolar coagulation, of umbilical cord, in multifetal pregnancies, 610–611

Moral certainty, 6–8

Moral issues, in maternal–fetal surgery for spina bifida
personhood, 451–452
religious context of, 452–453
risks, 457–458

Morality, versus ethics, 1–2

Motor development, follow-up data in, 227–229

Multifetal pregnancy, 623–641. *See also* Twin–twin transfusion syndrome.
causes of, 103–104
complications of, 624–625
costs of, 624–625
home uterine activity monitoring impact on, 765, 781–782
incidence of, 623
natural history of, 624–625
nuchal translucency screening in, 99
preterm birth in, 624, 658–659, 758
cervical ultrasound evaluation in, 746–747
fetal fibronectin in, 714–717
salivary estriol measurement in, 726
public fascination with, 104–105
reduction of
cervical length after, 634
chromosomal abnormalities and, 631–632
controversies in, 634–635, 638
ethics of, 633–634
follow-up after, 632–633
gestational age at delivery and, 628
historical aspects of, 625
intrauterine growth retardation and, 631
outcome of, 630–631, 636–637
pregnancy loss in, 626–630, 635–636
presenting fetus and, 635
psychological aspects of, 633
selective, 103–111, 635–639

technical aspects of, 625–626, 637–638
to singleton, 634
transvaginal, 630
vascular occlusion techniques for, 601–621
genetic counseling in, 604–606
in discordant twin anomalies, 603
in twin–twin transfusion syndrome, 596, 603–616
in twin reversed arterial perfusion sequence, 602–603
indications for, 602–604
methods for, 606–616
psychosocial aspects of, 616
risks in, 103
statistics on, 103

Myelomeningocele
hydrocephalus with, 533
maternal–fetal surgery for, 155–165, 521–530
developmental aspects and, 522–524
equipoise criterion in, 162–163
ethics of. *See* Ethics of maternal–fetal surgery, for spina bifida, future research on, 528
historical review of, 524–525
outcome of, 160–161
patient definition in, 156–160
randomized, controlled clinical trials of, 521–522, 527
research on, 160–163
results of
Chiari malformation, 526
hydrocephalus, 525–526
leg function, 526
morbidity and mortality, 526–527
risks of, 161–162

Myometrium
electrical properties of, 667–669
physiology of, 806–807

N
Narcotics, for preterm labor, 821–822
Narrative ethics, 7
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 49, 62–63
National ethics committees, 48–49

National Human Research Protections Advisory Committee, on maternal–fetal surgery research, 147–150
National Partnership to Help Smokers Quit, evidence-based decision-making in, 412–414
Nelfinavir, for HIV infection, in pregnancy, labor and delivery, 863
Neonatal intensive care unit
evidence-based decision-making in, 333–342
clinical research and, 336–337
evaluation of practice in, 340
ingredients of, 334–335
systematic reviews in, 335–336
using summarized evidence to inform clinical practice, 338–339
validity of protocols in, 339–340
level III, in managed care, 178

Neural tube defects. *See also* Myelomeningocele, in multifetal pregnancies, 605
Neurodevelopmental outcome, follow-up data in. *See* Evidence-based decision-making
Nevirapine, for HIV infection, in pregnancy, labor and delivery, 862, 864–867
Newborns
at threshold of viability, FIGO ethical guidelines for, 54–56
severely malformed, FIGO ethical guidelines for, 56–57
viability of. *See* Viability, of fetus or newborn
Nicardipine, for preterm labor, 821
Nifedipine, for preterm labor, 821, 849–850
Nitric oxide, for congenital diaphragmatic hernia, 475
Nomenclature. *See* Communication
Nuchal translucency screening, 95–102
reliability of, 95–98
respect for autonomy in, 100
risks versus benefits of, 98–99
Nuremberg Code, 59–60

O
Obstructive uropathy. *See* Urinary tract obstruction, distal
Octuplets. *See* Multifetal pregnancy
Oligohydramnios
in fetal distal urinary obstruction, 507–511, 515

in gastroschisis, 553–554, 561–564
in twin–twin transfusion syndrome, 591, 593
isolated, versus twin–twin transfusion syndrome, 593

O

Oncofetal fibronectin. *See* Fibronectin, fetal.

Oocytes, ultrasonography of, 39

Opioids, for preterm labor, 821–822

Ovulation induction, preterm birth risk in, 659

Oxygen therapy
for respiratory distress syndrome, treatment decisions in, 337
in delivery room, treatment decisions in. *See* Treatment decisions.

Oxytocin, in uterine activity, 806–807

Oxytocin receptor antagonists, for preterm labor, 849

P

Palpation, of uterine contractions, versus tocodynamometer system, 767–768

Partial liquid ventilation, for congenital diaphragmatic hernia, 474–475

Patient-physician relationship
in ethics codes, 46
in managed care, 168–169

Payment, of physicians, in managed care, 170–171

Percival, Thomas, ethics code of, 5

Periodontal infections, preterm birth in, 693–694

Peritonitis, in gastroschisis, 552

Perivisceritis, in gastroschisis, 553–554, 556–558, 560–561

Personality, definition of, 30–31

Phosphodiesterase inhibitors, for preterm labor, 821

Phospholipase A₂, in uterine activity, 807

Phototherapy, for low bilirubin levels, in low birth weight infants, treatment decisions in. *See* Treatment decisions.

Placenta
anastomoses of, in twin–twin transfusion syndrome, 592–593
circulation of, ultrasonography of, 40–41

Placometomegaly, in sacrococcygeal teratoma, 495–498

Platelet(s), in amniopatch, for premature membrane rupture, 574–580, 586–587

Platelet-derived growth factor, in congenital cystic adenomatoid malformation, 482

Plug the lung strategy, for congenital diaphragmatic hernia, 468

Polyhydramnios
in twin–twin transfusion syndrome, 591, 593
isolated, versus twin–twin transfusion syndrome, 593

Posterior urethral valves
evaluation of, 512–513
treatment of, 513–516

Potassium chloride, for multifetal pregnancy reduction
controversies in, 634–635
ethics of, 633–634
follow-up after, 632–633
from three to two, 630–631
genetic testing before, 631–632
gestational age at delivery and, 628
intrauterine growth retardation from, 631
pregnancy loss in, 626–630
psychological aspects of, 633
selective termination in, 635–639
technique for, 625–626
transvaginal, 630

Pre-certification, in managed care, 172–173

Pre-embryo, description of, 29–30

Predisposition to treatment, in maternal–fetal surgery for spina bifida, 460–461

Pregnancy. *See also* Uterus.
bleeding in, preterm birth in, 657
cervical length in, preterm birth and, 654
cervical ultrasound evaluation in, 735–755
drug abuse in, criminalization of, 157–158
fetal surgery during. *See* Maternal–fetal surgery.
genetic counseling related to. *See* Genetic counseling.
infections in, preterm birth and, 655–656
multifetal. *See* Multifetal pregnancy.
nuchal translucency screening in, 95–102
refusal of treatment during, 127–140
legal issues in, 128–134
survey of maternal–fetal fellowship directors on, 134–139
sudden maternal death in, FIGO ethical guidelines for, 53
tentative, prenatal diagnosis and, 22
termination of. *See* Abortion.

Preimplantation genetic diagnosis, **67-80**
 clinician's conscience and, 78-79
 description of, 67
 embryogenesis stages and, 29-30
 ethical issues in
 disclosure, 69
 in offering procedure, 68-70
 informed consent, 69
 moral status of extracorporeal
 embryo, 70-71
 reimbursement, 68-69
 socioeconomic status and, 69
 for desirable characteristics selection,
 75-77
 for sex selection, 75-77
 gene therapy and, 92
 marketing of, 68-69
 of serious diseases and disabilities,
 72-75
 purpose of, 71-72
 statistics on, 67

Premature infants, selective reduction and,
 106-107

Premature labor and delivery
 definition of, 665-666, 809-811
 diagnosis of, 810-812
 economic costs of, 666, 757-758
 epidemiology of, **651-664**, 677, 757
 history of, 653-654
 home uterine activity monitoring for,
 757-804
 in discordant twins, 603
 in HIV infection, **859-878**
 in maternal-fetal surgery, 527
 myelomeningocele, 527
 in multifetal pregnancies, 624, 628, 637
 in twin reversed arterial perfusion
 sequence, 602
 indicated versus spontaneous, 652
 infections causing. *See* Infections,
 preterm birth in.
 management of, **805-826**. *See also*
 Tocolysis.
 bedrest in, 813-814
 beta-sympathomimetic agents in,
 817-820
 calcium channel blockers in,
 820-821
 decisions in, 811-812
 ethanol in, 815-816
 fluid therapy in, 814
 future considerations in, 822-823
 goals of, 812-813
 magnesium sulfate in, 814-815
 phosphodiesterase inhibitors in, 821
 prostaglandin synthase inhibitors
 in, 816-817
 patterns of, 653

prediction of
 biochemical, **701-733**
 cervical ultrasound in, **735-755**
 predisposing factors in, 808-809
 prevention of
 corticosteroids for, 827-842
 tocolysis in, **843-855**
 recurrent, 653-654, 851
 risk factors for, 651-660
 spontaneous versus indicated, 652
 symptoms of, 766-767
 uterine contraction physiology in,
 665-676, 806-807

Premature ruptured membranes
 preterm, corticosteroids use in, 828-830
 treatment of, **573-589**, 691
 animal models of, 585-586
 iatrogenic, amniopatch for,
 574-580
 spontaneous, 580-587
 amniopatch for, 586-587
 endoscopic assessment for,
 580-584
 surgical, 584-587

Prenatal diagnosis. *See also* Fetus, anomalies
 of, screening and detection of;
 Preimplantation genetic diagnosis.
 communication about.

See Communication.
 FIGO ethical guidelines for, 52-53
 genetic counseling with, 82-84
 language used in, 20-24

Prenatal surgery. *See* Maternal-fetal surgery.

Presymptomatic diagnosis, ethical issues in,
 87-88

Preterm birth. *See* Premature labor
 and delivery.

Preventive health services, in managed
 care, 172

Principalism, 6-7

Progesterone, for preterm labor, 822

Prostaglandin(s)
 fetal need for, 817
 in uterine activity, 806-807, 809

Prostaglandin synthetase inhibitors, for preterm
 labor, 816-817, 848-849

Psychosocial issues
 in multifetal pregnancy reduction, 623
 in selective termination, 616

Pulmonary arteries, hypoplastic, treatment
 of, 546

Pulmonary atresia, with intact ventricular
 septum, treatment of, 546

Q

Quadruplets. *See* Multifetal pregnancy.

Quality management, in managed care, 171-172

Quintuplets. *See* Multifetal pregnancy.

R

Racial factors, in preterm birth, 651, 656-657

Radiofrequency ablation, of sacrococcygeal teratoma, 501-503

Reasoning, ethical, 3-5

Reduction, selective. *See* Selective termination.

Reimbursement, for preimplantation genetic diagnosis, 68-69

Religious context, of maternal-fetal surgery for spina bifida, 452-453

Religious teachings

genetic counseling and, 91-92
on beginning of life, 33-35

Research

on fetuses, ethics guidelines for, 62-63

on human subjects, international ethics codes for, 59-63

on maternal-fetal surgery. *See* Maternal-fetal surgery.

Respiratory distress syndrome

oxygen therapy for, treatment decisions in, 337

surfactant therapy for, treatment decisions in, 336-337

Ritodrine, for preterm labor, 819-820, 846

Ritonavir, for HIV infection, in pregnancy, labor and delivery, 863

Rodeck, Charles, maternal-fetal surgery research by, 440-441

Ruptured membranes

iatrogenic, between twins, for twin-twin transfusion syndrome, 596

premature. *See* Premature ruptured membranes.

S

Sacrococcygeal teratoma, 493-506

diagnosis of, 495-496

dystocia due to, 494

epidemiology of, 493

grading system for, 493

histology of, 493, 495

malignant, 494-495

maternal mirror syndrome and, 496-497

natural history of, 496

surgical treatment of, 497-504

Salivary estriol, as preterm birth predictor, 720-727

Saquinavir, for HIV infection, in pregnancy, labor and delivery, 863

Sedatives, for preterm labor, 821-822

Selective laser photocoagulation of communicating vessels, for twin-twin transfusion syndrome, 595-597

Selective termination, 103-111

controversy over, 103

in multifetal pregnancies

bipolar cord coagulation in,

611-616

controversies in, 638

counseling for, 604-606

embolization in, 606-608

fetoscopic cord ligation in, 607, 609

indications for, 602-604

laser photocoagulation of cord in,

607-608, 610

monopolar cord coagulation in,

610-611

outcomes of, 636-637

overlap with reduction, 638-639

pregnancy loss in, 635-636

psychosocial aspects of, 616

technical aspects of, 637-638

vascular occlusion techniques for.

See under Multifetal

pregnancy, reduction of.

outcomes of, 105-108

patient issues in, 108-109

procedures for, 105

Septostomy, for twin-twin transfusion syndrome, 496

Septuplets. *See* Multifetal pregnancy.

Sex, prebirth selection for, 75-77, 89

Sextuplets. *See* Multifetal pregnancy.

Sexually transmitted infections, preterm birth in, 691-694

Shunts

thoracoamniotic, for lung lesions,

485-486

ventriculoamniotic, in hydrocephalus,

534-538

vesicoamniotic, for distal urinary tract

obstruction, 513-515

Smoking

cessation of, in routine medical care,

evidence-based decision-making in,

414-415

preterm risk birth in, 659

Social development, follow-up data in, 230

Socioeconomic factors, in preterm birth, 656–657, 808

Spermatozoa, as being, controversy over, 35

Spina bifida

- hydrocephalus with, 533
- prenatal treatment of, 521–530
 - clinical trials of, 527
 - developmental aspects and, 522–524
 - ethics of. *See* Ethics, of maternal–fetal surgery, for spina bifida.
 - future research on, 528
 - historical review of, 524–525
 - results of
 - Chiari malformation, 526
 - hydrocephalus, 525–526
 - leg function, 526
 - morbidity and mortality, 526–527

Standards of care, in managed care, 171

State Child Health Insurance Program, fetal coverage considerations in, 157

Stavudine, for HIV infection, in pregnancy, labor and delivery, 859–860, 862

Stem cell research, ethical issues in, 36–37

Stillbirths, in maternal infections, 692–693

Sulindac, for preterm labor, 817, 848–849

Surfactant

- deficiency of, in congenital diaphragmatic hernia, 471, 475
- replacement of, for respiratory distress syndrome, treatment decisions in, 336–337

Surgery, maternal–fetal. *See* Maternal–fetal surgery.

Susceptibility testing, for genetic disorders, ethical issues in, 87–88

T

Tenovovir, for HIV infection, in pregnancy, labor and delivery, 862

Teratoma, sacrococcygeal, 493–506

Terbutaline

- for preterm labor, 819–820, 846–847
- for tocolysis, home uterine activity monitoring during, 793–797

Tetralogy of Fallot, treatment of, 546

Therapeutic evidence. *See also* Evidence-based decision-making; Treatment decisions. statistics in, 205–215

- adjusting for baseline differences, 211–212
- appropriateness of analysis, 210
- confounding variables, 211–212
- number needed to treat, 213
- observational studies, 213–214
- P* value greater than 0.05, 208–210
- P* value less than 0.05, 206–208
- randomized trials, 212–213
- rationale for, 205–206

Thermocoagulation

- of sacrococcygeal teratoma, 501, 503
- of umbilical cord, in
 - multifetal pregnancies
 - bipolar, in multifetal pregnancies, 611–616
 - monopolar, 610–611

Thoracoamniotic shunting, for lung lesions, 485–486

Tocodynamometers

- for home uterine contraction monitoring. *See* Home uterine activity monitoring.
- for preterm labor detection, 667

Tocolysis

- bedrest in, 813–814
- beta-adrenergic agents in, 846–848
- beta-sympathomimetic agents in, 817–820
- calcium channel blockers in, 820–821, 849–850
- decisions about, 810–812
- ethanol in, 815–816
- fluid therapy in, 814
- future considerations for, 822–823
- goals of, 812–813
- home uterine activity monitoring after, 787–791
- home uterine activity monitoring during, 793–797
- magnesium preparations in, 814–815, 848
- maintenance, 843–856
 - beta-adrenergic agents in, 846–848
 - calcium channel blockers in, 849–850
 - literature review on, 844–846
 - magnesium in, 848
 - oxytocin receptor antagonists in, 849
 - prostaglandin synthetase inhibitors in, 848–849
 - results of, 850–855
 - oxytocin receptor antagonists in, 849

phosphodiesterase inhibitors in, 821
prostaglandin synthetase inhibitors in, 816–817, 848–849

Tracheal occlusion procedure, for congenital diaphragmatic hernia, 468–473

Transfusions, refusal of, in pregnancy, 130–131, 135

TRAP (twin reversed arterial perfusion sequence), vascular occlusion techniques for, 602–603

Treatment

- refusal of, during pregnancy, 127–140
- withholding or withdrawal of
 - for newborns at threshold of viability, ethics of, 54–55
 - for severely malformed newborns, ethics of, 56–57

Treatment decisions, 351–361. *See also* Evidence-based decision-making; Therapeutic evidence; controlled human experiments in, historical aspects of, 354–355 evidence versus practice in, 305–331 antibiotics in asymptomatic

- premature infants, 322–325
- current practice, 324–325
- evidence against, 323–324
- evidence supporting, 322–323
- future practice, 325
- quality of evidence, 325
- recommendations, 325

delivery room-assisted ventilation with 100% oxygen, 319–322 current practice, 321 evidence against, 319–321 evidence supporting, 319 future practice, 321 quality of evidence, 322 recommendations, 322 inotropes for hypotension in premature infants, 311–314 current practice, 314 evidence against, 312–314 evidence supporting, 311–312 future practice, 314 quality of evidence, 314 recommendations, 314 methylxanthines for neonatal apnea, 309–311 current practice, 311 evidence against, 310–311 evidence supporting, 309–310

future practice, 311
quality of evidence, 311
recommendations, 311
phototherapy in extremely low birth weight infants, 305, 307–309 current practice, 309 evidence against, 307–308 evidence supporting, 305, 307 future practice, 309 quality of evidence, 309 recommendations, 309 therapy for gastroesophageal reflux, 314–316 current practice, 318 evidence against, 316–318 evidence supporting, 314–316 future practice, 318 quality of evidence, 318–319 recommendations, 319 in public health interventions, 355–357 randomized trials in, 357–358 obstacles to, 358–359 observational studies and, 269–283 case-control studies in, 276–277 cautionary notes in, 280–281 cohort studies in, 274–276 effect size in, 278 evidence of causal association in, 277–278 external validity in, 273 internal validity in, 272–273 lack of other explanations in, 279–280 population-wide data in, 279 reporting analytical studies in, 280 temporal proximity of treatment and outcome in, 278 types of research designs in, 270–271 value of ecologic designs in, 278–279 versus experimental analyses, 352–354 when randomized, controlled trial not possible, 273

risks versus benefits of, 251–268 assessing values attached to outcomes, 260, 262 integrating values into decisions, 262–267 measuring effects of, 254–257 minimum event need to justify treatment, 257–258 threshold number needed to treat, 257 derivation of, 258–259 factors influencing, 259

Triplets. *See* Multifetal pregnancy.

Trisomy 13, abortion decision-making in, 121-122

Trisomy 18, abortion decision-making in, 121-122

Trisomy 21. *See* Down syndrome.

Trust, in ethics, 8-9

Tumor(s)

- congenital cystic adenomatoid malformation, of lung, 481-492
- sacrococcygeal teratoma, 493-506

Tumor necrosis factor- α , in gastroschisis, 557-558, 562-563

Twin(s). *See also* Multifetal pregnancy.

- preterm birth risk for, 658-659
- cervical ultrasound evaluation in, 746-747
- fetal fibronectin measurement in, 714-717
- triplet pregnancy reduced to, 630-631

Twin-twin transfusion syndrome, 591-600

- chromosomal abnormalities in, 605-606
- definition of, 591-592
- diagnosis of, 593
- differential diagnosis of, 593
- etiology of, 592-593
- in multifetal pregnancies, 591
- incidence of, 592, 603
- mortality in, 594, 597
- pathophysiology of, 604
- reversed arterial perfusion sequence in, 602-603
- staging of, 593-594
- treatment of, 594-597, 604
- early development of, 445-446
- laser therapy in, 595-597
- septostomy in, 596
- serial amniocentesis in, 594-597
- single fetal demise in, 597
- umbilical cord occlusion in, 596, 606-616

Twin reversed arterial perfusion sequence, vascular occlusion techniques for, 602-603

U

Ultrasonography

- fetal
- bonding during, 21
- in chromosomal abnormalities, in multifetal pregnancies, 605
- in congenital cystic adenomatoid malformation, 482-483
- in congenital diaphragmatic hernia, 466-467

- in congenital heart disease, 542-543
- in distal urinary tract obstruction, 510, 512
- in early human development, 37-42
- in gastroschisis, 553
- in genetic counseling, 82-84
- in hydrocephalus, 532-533
- in nuchal translucency screening, ethical dimensions of, 95-102
- in sacrococcygeal teratoma, 495
- in selective reduction, 105
- in twin-twin transfusion syndrome, 593
- indications for, in managed care, 177-178
- insensitive terms used in, 19
- maternal, in cervical evaluation, 735-755

Umbilical cord

- occlusion of, for twin-twin transfusion syndrome, 596
- procedures involving, in multifetal pregnancies
- bipolar cord coagulation, 611-616
- laser photocoagulation, 607, 610
- ligation, 607, 609
- monopolar coagulation, 610-611

United Nations Educational, Scientific, and Cultural Organization (UNESCO), ethics code of, 50

Urethra

- abnormalities of. *See* Urinary tract obstruction, distal.
- embryology of, 508

Urinalysis, in distal urinary tract obstruction, 512-513

Urinary tract infections, maternal, preterm birth in, 693

Urinary tract obstruction, distal, 507-519

- animal models of, 508-510
- diagnosis of, 510-511
- differential diagnosis of, 511
- embryologic considerations in, 508
- etiology of, 507
- morbidity and mortality from, 507
- treatment of, 511-516
- cystoscopy in, 515-516
- evaluation for, 511
- in posterior urethral valves, 512-513
- rationale for, 512-513
- vesicoamniotic shunting in, 513-515

Uterus

anomalies of, preterm birth and, 657–658
contractions of, 665–676
Braxton Hicks, 809–810
electromyography of, 670–674
frequency of, preterm birth and, 658
home monitoring of. *See Home uterine activity monitoring*.
in labor diagnosis, 666–667
in preparatory stage, 669–670
model for, 669–670
myometrial physiology in, 667–674
physiology of, 806–807
overdistention of, preterm birth in, 809
structural defects of, preterm labor in, 808–809

Utilitarianism, 6**V**

Vagina, fibronectin in. *See Fibronectin, fetal*.
Vaginal bleeding, preterm birth in, 657
Vaginosis, bacterial, preterm birth in, 655–656, 686–687, 690–691
Valvuloplasty, balloon, for congenital heart disease
evaluation for, 542–543
left-sided, 544–546
rationale for, 543–544
right-sided, 546
techniques for, 547–548
Vascular occlusion techniques, for multifetal pregnancies. *See under Multifetal pregnancy, reduction of*.

Ventilation, in delivery room, treatment decisions in. *See Treatment decisions*.
Ventricular septum, intact, treatment of, 546
Ventriculoamniotic shunt, in hydrocephalus, 534–538
Ventriculomegaly, in hydrocephalus, 532
Vesicoamniotic shunt, for distal urinary tract obstruction, 513–515
Viability, of fetus or newborn
anencephalic, 119–121
at threshold, FIGO ethical guidelines for, 54–56
federal definition of, 147
legal definition of, 119–122

patient status and, 159–160

with anomalies
counseling after, 122–124
counseling before, 118–119

Video-assisted fetal endoscopy, for congenital diaphragmatic hernia, 468

Viral infections, preterm birth in, 694

Virtue ethics, 7

Vision assessment, follow-up data in, 227

Visual analog scale, and treatment decisions, 260

Vulnerability, in maternal–fetal surgery for spina bifida, 454–455

W

Warnock Committee on Human Fertilization and Embryology, 49

Withholding or withdrawal of care
for newborns at threshold of viability, ethics of, 54–55
for severely malformed newborns, ethics of, 56–57

World Association of Perinatal Medicine, Ethical Committee of, 51

World Health Organization, ethics code of, 50–51

World Medical Association, Declaration of Helsinki, 60–63

Y

Yolk sac, ultrasonography of, 39–40

Z

Zalcitabine, for HIV infection, in pregnancy, labor and delivery, 862

Zidovudine, for HIV infection in neonates, 870, 872
in pregnancy, labor and delivery, 860–862, 864–870

Zygote, as beginning of human life, 31–32

Zygote intra-fallopian transfer, preterm birth risk in, 659

